How Doping Affects Athletic Performance: Substances, Risks, and Testing

Introduction

Doping refers to the use of substances or methods that are prohibited by sports governing bodies because they are believed to enhance athletic performance, present health risks, or violate the spirit of sport. The practice has accompanied competitive athletics throughout history—ancient Greek Olympians reportedly consumed special preparations to improve performance—but doping in the modern sense is a product of the pharmaceutical industry's capacity to synthesize and supply hormones, stimulants, and other biologically active compounds at scale. Despite decades of increasingly sophisticated anti-doping efforts, doping remains a persistent challenge at the highest levels of sport, raising questions about fairness, health, governance, and the meaning of athletic achievement.

Major Categories of Banned Substances

Anabolic-Androgenic Steroids

Anabolic-androgenic steroids are synthetic variants of testosterone, the primary male sex hormone. They promote nitrogen retention in muscle tissue, accelerating muscle protein synthesis. Users can gain substantial lean muscle mass and strength in weeks when combined with resistance training—effects that would take months or years through training alone. AAS also accelerate recovery from intense training by reducing muscle damage and inflammation.

The health risks of AAS are well-documented and serious:

• Cardiovascular: Left ventricular hypertrophy, elevated LDL cholesterol, reduced HDL cholesterol, increased risk of heart attack and stroke. AAS abuse is associated with cardiomyopathy and sudden cardiac death.
• Liver: Oral AAS (17-alpha-alkylated) are hepatotoxic; peliosis hepatis, cholestasis, and hepatocellular carcinoma have been reported.
• Endocrine: Suppression of natural testosterone production; testicular atrophy; infertility in males. In females: virilization (voice deepening, facial hair, clitoral enlargement), menstrual disruption.
• Psychological: Aggression, mood instability, and dependence.

EPO and Blood Doping in Endurance Sports

Erythropoietin (EPO) is a hormone produced by the kidneys that stimulates red blood cell production. Recombinant human EPO (rhEPO), developed in the 1980s as a treatment for anemia, was rapidly adopted by endurance athletes because red blood cells carry oxygen to working muscles. Increasing red blood cell count—whether through synthetic EPO or through blood transfusions (autologous: reinfusing the athlete's own stored blood; homologous: using another person's blood)—can improve maximal oxygen consumption (VO₂max) and endurance performance by 5–10 percent.

The 1998 Tour de France "Festina affair," in which a team car was found carrying quantities of EPO and other drugs at the border, was a watershed moment that forced cycling to confront its systemic doping culture. Lance Armstrong's subsequent dominance of the Tour de France (1999–2005), built on a comprehensive doping program, and his eventual confession in 2013 remains the most high-profile doping scandal in sports history. Armstrong was stripped of all seven Tour titles.

The Anti-Doping System

The World Anti-Doping Agency (WADA) was established in 1999 following the Festina scandal as an independent body to coordinate anti-doping policy globally. The World Anti-Doping Code, first adopted in 2003 and revised in 2009, 2015, and 2021, provides the framework within which all sports governing bodies and national anti-doping organizations operate.

Testing methodology includes:

• Urine analysis: The primary testing matrix; detects most prohibited substances and their metabolites.
• Blood passport: Longitudinal monitoring of athletes' blood parameters over time; abnormal patterns indicate manipulation even when no substance is detected in a single test.
• Blood testing: Required for EPO and growth hormone detection.
• Out-of-competition testing: Athletes in many sports must provide their whereabouts to anti-doping authorities and are subject to testing at any time, including during training periods.

Detection Challenges

• Microdosing: Using substances in quantities below detection thresholds; EPO microdosing is a known tactic in cycling.
• Designer steroids: Chemists can synthesize modified AAS not yet on the prohibited list or not detected by current tests.
• Gene doping: Theoretical use of gene therapy to alter gene expression—e.g., increasing EPO production naturally. Currently undetectable.
• Sample storage: WADA stores samples for ten years, allowing re-testing as detection methods improve. This retrospective testing has revealed numerous doping violations years after competitions.

Major Doping Scandals

The 2015 McLaren Report, commissioned by WADA, documented a state-sponsored doping program by Russia that involved the systematic manipulation of urine samples during the 2014 Sochi Winter Olympics. The scandal led to Russian athletes competing under neutral flags at multiple subsequent Games and remains the most extensive state-level doping operation ever documented.

Doping is fundamentally a governance challenge as much as a scientific one. As long as the rewards for athletic success remain enormous and the probability of detection imperfect, some athletes will seek chemical advantages. The ongoing evolution of anti-doping science and policy reflects the perpetual tension between those pressures and the ideal of clean, fair competition.